IL17A and systemic lupus erythematosus: Due to the proven significant role of IL17 and IL23 in the pathogenesis of SLE and the success of these antibodies in clinical trials studying the treatment of other autoimmune diseases, there is potential for the use of these antibodies for the treatment of SLE with preliminary clinical trials.